| CAS NO: | 356-12-7 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 2g | 电议 |
| 10g | 电议 |
| Molecular Weight (MW) | 494.52 |
|---|---|
| Formula | C26H32F2O7 |
| CAS No. | 356-12-7 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 99 mg/mL (200.2 mM) |
| Water: <1 mg/mL | |
| Ethanol: N/A | |
| Other info | Chemical Name: 2-((2S,6aS,6bR,7S,8aS,8bS,11aR,12aS,12bS)-2,6b-difluoro-7-hydroxy-6a,8a,10,10-tetramethyl-4-oxo-2,4,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-2-oxoethyl acetate InChi Key: WJOHZNCJWYWUJD-IUGZLZTKSA-N InChi Code: InChI=1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1 SMILES Code: CC(OCC([C@@]12[C@H](OC(C)(C)O2)C[C@@H]3[C@]1(C)C[C@H](O)[C@@]4(F)[C@H]3C[C@H](F)C5=CC(C=C[C@@]54C)=O)=O)=O |
| Synonyms | Lidex, Lyderm, Metosyn, Topsyn, Fluocinolide, Vanos, Lonide |
| In Vitro | In vitro activity: Fluocinonide cream has a lower potential to produce atrophic changes of the skin than either clobetasol cream or clobetasol propionate foam. Fluocinonide (Vanos) is a potent glucocorticoid steroid used topically as anti-inflammatory agent for the treatment of skin disorders. Target: Glucocorticoid Receptor Fluocinonide is a potent glucocorticoid steroid used topically as an anti-inflammatory agent for the treatment of skin disorders such as eczema and seborrhoeic dermatitis. Fluocinonide ranks as a 'high-potency' topical corticosteroid. Minimal amounts should be used for a minimal length of time to avoid the occurrence of adverse effects. Fluocinonide should not be used if infection is present. Fluocinonide is used in veterinary medicine. It is a treatment for allergies in dogs. Natural systemic cortisol concentrations can be suppressed for weeks after one week of topical exposure. |
|---|---|
| In Vivo | Fluocinonide causes prompt and sustains pituitary-adrenocortical suppression in healthy dogs. Fluocinonide results in significant reduction of plasma cortisol and iACTH concentrations by day 2 of treatment in healthy dog, and the lower concentrations continued to day 5. One week after the last application of Fluocinonide, plasma iACTH concentrations in the corticosteroid-treated dogs has returned to the range of values for the control dogs; however, pre- and post-ACTH cortisol concentrations remains suppressed in Fluocinonide treated dogs. Two weeks after the last treatment, the pre-ACTH plasma cortisol concentrations of corticosteroid-treated dogs returns to those of the control dogs, but the post-ACTH plasma cortisol concentrations remains suppressed. |
| Animal model | Dogs |
| Formulation & Dosage | |
| References | J Drugs Dermatol. 2008 Jan;7(1):28-32; J Drugs Dermatol. 2008 Jan;7(1):28-32. |
m.cnreagent.com